Volume 66, Issue 6, Pages (June 2017)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells Chun-Yu Liu,

Volume 59, Issue 1, Pages (July 2013)

Volume 63, Issue 1, Pages (July 2015)

Inflammasomes in liver diseases

Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes J. Kim, M. Xu, R. Xo, A. Mates, G.L.

Fig. 4. Effect of Mcl-1 overexpression on H2O2-induced JNK activation and apoptosis. (A) Expression of Mcl-1 protein in several.

Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.

The GAPs between hepatocellular carcinoma and RAS

Inflammation and Cancer: IL-6 and STAT3 Complete the Link

Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells Wen-Jane Lee, PhD, Hsiu-Chung.

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Caspase‐2 activation is a prerequisite for TRAIL‐mediated apoptosis.

Volume 44, Issue 3, Pages (March 2006)

Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells Wen-Jane Lee, PhD, Hsiu-Chung.

Volume 64, Issue 6, Pages (June 2016)

Volume 52, Issue 3, Pages (March 2010)

Jean-Charles Nault, Jessica Zucman-Rossi Journal of Hepatology

RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,

Cross-Regulation of Proinflammatory Cytokines by Interleukin-10 and miR-155 in Orientia tsutsugamushi-Infected Human Macrophages Prevents Cytokine Storm

Florie Borel, Pavlina Konstantinova, Peter L.M. Jansen

Volume 41, Issue 3, Pages (September 2004)

Cell Physiol Biochem 2016;39: DOI: /

Volume 56, Issue 3, Pages (March 2012)

Volume 134, Issue 1, Pages (January 2008)

Volume 44, Issue 2, Pages (February 2006)

JAK inhibitors in dermatology: The promise of a new drug class

Interferon-γ Protects from Staphylococcal Alpha Toxin-Induced Keratinocyte Death through Apolipoprotein L1 Anne M. Brauweiler, Elena Goleva, Donald Y.M.

The place of downstaging for hepatocellular carcinoma

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

Tie2-R849W Mutant in Venous Malformations Chronically Activates a Functional STAT1 to Modulate Gene Expression Hsiao-Tang Hu, Yi-Hsien Huang, Yi-Ann.

Volume 65, Issue 4, Pages (October 2016)

Volume 60, Issue 6, Pages (June 2014)

Signalling pathways in alcohol-induced liver inflammation

Volume 64, Issue 6, Pages (June 2016)

Targeting gut flora to prevent progression of hepatocellular carcinoma

The IL-17F signaling pathway is involved in the induction of IFN-γ–inducible protein 10 in bronchial epithelial cells Mio Kawaguchi, MD, Fumio Kokubu,

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study Gyuri Kim, Suk-Yong Jang, Chung.

Why men are at higher risk for hepatocellular carcinoma?

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Volume 44, Issue 1, Pages (January 2006)

Genomic risk of hepatitis C-related hepatocellular carcinoma

The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin Anjaiah Srirangam, PhD,

Volume 43, Issue 4, Pages (October 2005)

Volume 26, Issue 2, Pages (February 2018)

Volume 41, Issue 3, Pages (September 2004)

Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid Anne-Kathrin Kienzler, MSc, Marta Rizzi, MD,

Volume 26, Issue 2, Pages (February 2018)

Met as a therapeutic target in HCC: Facts and hopes

Xiaolong Wei, Hai Xu, Donald Kufe Cancer Cell

Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…

Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes J. Kim, M. Xu, R. Xo, A. Mates, G.L.

Nehad Abdulgader Shaer Pathophysiology

Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin Y. Luan, Ph.D., M.D., L. Kong, Ph.D.,

Molecular prognostication of liver cancer: End of the beginning

Evolution of liver transplantation for hepatocellular carcinoma

Molecular Therapy - Nucleic Acids

Volume 60, Issue 5, Pages (May 2014)

Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma

Volume 41, Issue 6, Pages (December 2004)

3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6–type cytokine actions by targeting the glycoprotein 130 subunit: Potential clinical implications

Volume 41, Issue 5, Pages (November 2004)

Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504

Genetics of hepatocellular carcinoma: The next generation

Volume 66, Issue 3, Pages (March 2017)

Volume 26, Issue 10, Pages (October 2018)

Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small- Cell Lung Cancer Cheng-Yi Wang, MD, Ting-Ting Chao, PhD, Wei-Tien.

Volume 17, Issue 5, Pages (March 2007)

Sorafenib inhibits cell proliferation and induces apoptosis in HCC cells. Sorafenib inhibits cell proliferation and induces apoptosis in HCC cells. A,

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Volume 66, Issue 6, Pages 1334-1335 (June 2017) Erratum to: Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Hsiang-Po Huang, Jui-Wen Huang, Pei-Jer Chen, Kuen-Feng Chen Journal of Hepatology Volume 66, Issue 6, Pages 1334-1335 (June 2017) DOI: 10.1016/j.jhep.2017.02.021 Copyright © 2017 Terms and Conditions

Fig. 4 SC-1 down-regulates p-STAT3 and induces apoptosis in HUVEC cells. (A) Effects of sorafenib or SC-1 on p-STAT3 (left panel) and apoptosis (right panel) in HUVEC cells. Cells were exposed to sorafenib or SC-1 at 10μM for 24h. Apoptotic cells were assayed by flow cytometry (sub-G1). (B) Effects of SC-1 on TRAIL sensitization in HCC. PLC5 cells were treated with SC-1 (10μM) and/or TRAIL (100ng/ml) for 24h. (C) Silencing Raf-1 does not affect the effects of the drugs on p-STAT3. PLC5 cells were transfected with control siRNA or Raf-1 siRNA for 24h then treated with sorafenib or SC-1 at 10μM for 24h. (D) Effect of sorafenib and SC-1 on JAK2 activity. PLC5 cells were exposed to sorafenib or SC-1 at 10μM for 24h. Points, mean; bars, SD (n=6). (E) Effects of sorafenib and SC-1 on SOCS-1 and SOCS-3. Sk-Hep1 cells were pre-treated with IL-6 for 24h then were treated with sorafenib or SC-1 at the indicated doses for another 24h in the presence of IL-6. (F) Effects of STAT-C on apoptosis induced by SC-1 in PLC5 cells. Cells (wild type or ectopic expression of STAT3-C) were exposed to sorafenib or SC-1 at 10μM for 24h. (G) Effects of sorafenib and SC-1 on SHP-1. Columns, mean; bars, SD (n=3) *p<0.05. Journal of Hepatology 2017 66, 1334-1335DOI: (10.1016/j.jhep.2017.02.021) Copyright © 2017 Terms and Conditions